Inherited BRCA2 mutations predispose individuals to breast cancer and increase risk at other sites. Recent studies have suggested a role for the APC I1307K allele as a low-penetrance breast cancer susceptibility gene that enhances the phenotypic effects of BRCA1 and BRCA2 mutations. To model the consequenc es of inheriting m utant alleles of the BRCA2 and APC tumor suppressor genes, we exam ined tumor outcom e in C57BL/6 mice with mutations in the Brca2 and Apc genes. We hypothesized that if the Brca2 and Apc genes were interacting to in uence mammary tumor susceptibility, then mammary tumor incidence and/or multiplicity would be altered in mice that had inherited m utations in both genes. Female and male offspring treated with a single IP injection of 50 mg/kg N-ethyl-N-nitrosourea (ENU) at 35 days of age developed mammary adenoacant homas by 100 days of age. The fem ale Apc-mutant and Brca2/Apc double-m utant progen y had m ean mammary tumor m ultiplicities of 6.7 2.8 and 7.2 2.7, respectively, compared to wild-type and Brca2-mutant females, which had mean mammary tumor multiplicities of 0.1 0.4 and 0.3 0.5, respectively. Female ENU-treated Apc-mutant and Brca2/Apc double heterozygo tes were also susceptible to prem ature ovarian failure. Thus, the inheritance of an Apc m utation predisposes ENU-treated female and male mice to m ammary tumors and, in the case of fem ale mice, to ovarian failure. These results indicate that mamm ary tum or developme nt in Apc-mutant mice can progress independen tly of ovarian hormones. The Apc mutation-driven phenotype s were not m odi ed by mutation of Brca2, perhaps because Brca2 acts in a hormonally dependen t pathway of mamm ary carcinogen esis.
INTRODUCTION
Inherited mutations in the human breast cancer susceptibility gene, BRCA2, profoun dly predispose wom en to the development of breast cancer. Women who inherit mutations in the BRCA2 gene have been reported to have a lifetime risk for breast cancer as high as 85% (32) , while for men the risk is approximately 7% (9) . In addition, BRCA2 alterations have been associated with cancer susceptibility at other sites, including the ovary, stomach, larynx, colon, and prostate (41) . W hile the function of the BRCA2 protein has yet to be elucidated, it is believed to play a role in tum or suppression, in DNA damage repair, and in the maintenance of genomic stability (22, 37, 40) .
Genes in the Wnt/APC/ -catenin-signaling pathway have been evaluated for their association with breast cancer development (1, 4, 10, 19, 41) . The APC gene has been suggested to be a low-penetrance breast cancer susceptibility gene or a modi er of the BRCA loci (33, 45) in addition to its well-established role in familial and sporadic colon cancer (14, 29) . Breast cancer patients who inherit the I1307K polymorphic APC allele are twice as likely to carry a m utation in one of the breast cancer susceptibility genes, BRCA1 or BRCA2, com pared to the general population. The APC I1307K allele polym orphism occurs in approxim ately 7% of the Ashkenazi Jewish population. Caused by an inherited T-to-A transversion at nucleotide 3920, this polym orphism creates an unstable poly A tract that is susceptible to m utation, apparently by polymerase slippage during DNA replication (21) . Such polymerase slippage is hypothesized to cause fram eshift m utations that disrupt the APC gene product.
Brca2 and Apc m ouse m odels have been developed to study the consequences of inherited mutations in these tum or suppressor genes. There have been no reports of increased m ammary tumor development, either spontaneous or induced, in mouse models created to study m utations in the endogenous Brca2 gene (15) . However, two Apc-mutant mouse strains are susceptible to carcinogeninduced mamm ary and ovarian tumor developm ent (27, 43) . Apc-m utant Min/ mice carry a nonsense mutation at codon 850 on a C57BL/6 genetic background (C57BL/ 6 (Apc ) and are susceptible to mammary tumor induction by the alkylating agent N-ethyl-N-nitrosourea (ENU) (26, 27) . Female Apc1638N mutant mice on a C56BL/6 genetic background display a 16-fold increase in mamm ary tum or incidence after treatment with 5 Gy radiation at 7 weeks of age (43) . In addition, radiation-treated (BALB/ c Apc1638N )F1 m ice developed ovarian tumors, while F1s from crosses with several other inbred strains did not (44) . Thus, genetic m odi ers from different inbred strain backgrounds in uence susceptibility to ovarian cancer in Apc1638N mice (44) .
Since the APC and BRCA2 genes have been suggested to interact to alter breast cancer risk in the human population, it was reasoned that a mouse m odel in which mutations in both genes were inherited would display an increased susceptibility to m ammary tumor induction. To examine this possibility, we bred C57BL/6 (B2 ) and C57B L/6 (Apc ) m ice to generate a mouse model for the germline inheritance of Brca2 and Apc gene alterations. Using this model, we sought to determine if coinheritance of Brca2 and Apc m utations would modify m amm ary ductal morphogenesis and/or tumor development compared to the parental or wild-type strains. Ovarian pathology was also evaluated since an Apc mouse model has been described to be sensitive to ovarian tumors after radiation. ENU treatm ent of the F1 offspring caused distinct mammary and ovarian phenotypes in m ale and female Apc-m utant and Brca2/Apc double-heterozygous mice.
M ATERIALS AND METHODS
Mice. C57BL/6 B2 female mice with a targeted mutation in exon 10 of the Brca2 gene were established in our laboratory by successive backcrossing of a chim eric male m ouse to the C57BL/6NCI (Charles River, Raleigh, NC) m ouse strain (3). C57BL/6 (B2 ) female mice were bred to C57BL/6J-Apc Min (C57B L/6 (Apc ) ) m ale mice (Jackson Laboratory, Bar Harbor, ME) to generate four genotypic classes of offspring: C57BL/6 (B2 / )(Apc / ) (wild type), C57B L/6 (B2 )(Apc / ) (Brca2 de cient), C57BL/6 (B2 / )(Apc ) (Apc mutant), and C57BL/6 (B2 )(Apc ) (double heterozygotes). The female C57BL/6 (B2 ) mice used in this experiment were N6-progeny backcrossed to the C57BL/ 6NCI inbred mouse strain. The mice were group housed in plastic cages, with a 12-hour on-off light cycle, and fed Picolab Mouse Diet 20 (20% protein, 9% fat, 4% crude ber; PMI Nutrition International, Brentwood, MO) and water ad libitum .
ENU Treatment: The m ice were treated with a single IP injection of 50 m g/kg ENU (Sigma, St. Louis, MO) between 35 and 40 days of age and were sacri ced at 100 days of age by CO 2 asphyxiation. At the time of sacri ce, the mammary glands were examined and tumors mapped, enumerated, measured, and dissected. The tumors were isolated, and, if large enough, a portion was sectioned off and snap frozen in liquid nitrogen. The fourth inguinal mamm ary gland fat pads were dissected away from the pelt, placed on glass slides, and submerged in 70% ethanol. In addition to the m ammary glands, the reproductive tract, pancreas, and adrenal glands from these mice were prepared for histology.
Whole-M ount Analysis of Mammary Glands: M ammary gland whole m ounts were prepared from the fourth abdominal m ammary gland using a procedure adapted from Bannerjee et al (2) . A longitudinal ventral incision along the midline was m ade in the skin that extended from the genital to the thoracic region. An inverted Vshaped cut was made on either side of the genetalia. The skin was peeled back and secured to an approxim ately 8 10-cm cardboard support and the carcass removed. After enumeration, mapping, and isolation of the m ammary tumors, the fourth mammary fat pad was dissected from the pelt using surgical scissors and forceps. Once isolated, the glands were placed either on glass slides or in histocassettes and submerged into 70% ethanol. After 72 hours in 70% ethanol, the mammary glands were xed in a 1:3 solution of 100% EtOH:acetic acid for 1 hour. Alternatively, on isolation, the glands could have been xed in neutral buffered form alin for 18-48 hours. The mamm ary glands were washed for 15 m inutes each in 70% and 50% ethanol followed by a nal rinse in doubledistilled water. The glands were then stained with room tem perature carmine red stain (2.5 g alum potassium sulfate, 1 g carmine, and dH 2 0 to a nal volume of 500 ml, boiled for 25 minutes, ltered through W hatm an #1 paper, and stored at 4 C) for 48 hours or until the fat pad was a uniform pink color. After staining, the m ammary glands were rinsed twice for 15 minutes in 70% ethanol, followed by 15-m inute washes in 90% and 100% ethanol. The mammary glands were then placed in xylenes for clearing and mounted as soon as 1 hour after transfer. The mammary glands were mounted on 2 3-inch glass slides with Perm ount (Fisher Scienti c) and covered with a 1 1-inch coverslip. Alternatively, they can be stored in glycerol or m ethylsalicylate. If m ounted using Permount, they are allowed to air dry in a hood for approximately 1 m onth.
Histology: The mammary gland tum ors, reproductive tract, pancreas, and adrenal glands were placed in 10% neutral buffered formalin for 24 hours and processed for routine histology. After the mammary gland whole mounts had been examined with a dissecting microscope, mamm ary gland sections that had apparent preneoplastic or neoplastic nodules were selected for histology. The mamm ary glands were released from the permount using xylene and rinsed in 100% ethanol for 30 minutes. They were rinsed for 30 minutes each in 95%, 80%, and 70% ethanol and then processed for routine histology. Fullface 5-micron sections were m ounted on slides and stained with hematoxylin and eosin.
Statistics: Because the distribution of mamm ary tumor multiplicity in the wild-type and Brca2-de cient genotypes were skewed and had m any zero values, com parisons among the four genotypic classes for m amm ary tumor m ultiplicity were made using the nonparametric Mann-W hitney U -test and Kruskal-Wallis test (39) . Comparisons of the incidences of reproductive pathologies among genotypic classes were m ade using the chi-square analysis. Initial body weights, nal body weights, and weight gains were com pared using Fisher's least signicant difference (LSD) test (24) .
RESULTS

Body Weight
C57BL/6 (B2 ) and C57BL/6 (Apc ) m ice were mated to generate 4 genotypic classes of offspring: C57BL/6 (B2 / ) (Apc / ) (wild type), C57B L/6 (B2 )(Apc / ) (Brca2 de cient), C57B L/6 (B2 / )(Apc ) (Apc mutant), and C57BL/6 (B2 )(Apc ) (double heterozygotes). The mean body weights did not differ among the 4 genotypic classes of m ice at the time of ENU injection. The mean body weight for each of the genotypic classes of m ice at the time of ENU injection 1.9. Analysis of variance (ANOVA) indicated a signi cant effect from the Apc mutation. Body weight was not affected by the inheritance of a Brca2 mutation, and no interaction was observed between Apc and Brca2 with regard to body weight or weight gain. Pairwise com parisons using Fisher's LSD test indicated a statistical difference between the Apc-mutant animals and the wild-type and Brca2-de cient animals (p 0.05). However, the Brca2/Apc double-heterozygous class did not differ signi cantly from the other groups. Thus, the presence of an Apc mutation did not have a predominant in uence on body weight in this experiment.
Mammary Tumor Incidence and Multiplicity in C57BL/ 6 (B2 ) C57BL/6 (Apc ) Male and Female Offspring Female mice that inherited an Apc m utation developed mammary tumors with 100% incidence with an average multiplicity of 6.7 2.8 65 days after ENU treatm ent ( Table 2 and Figure 1 ). ENU -treated female mice with inherited mutations in both Brca2 and Apc genes also developed mammary tumors with 100% incidence and a mammary tumor multiplicity of 7.2 2.7, which was not statistically different from m ice with an Apc mutation alone. There were no obser ved differences in tumor size distribution between the Apc-and Brca2/Apc double mutants. The wild-type and Brca2-de cient mice were rel-atively resistant to mammary tum or induction by ENU. Fem ale wild-type and Brca2-de cient mice had mammary tum or incidences of 7% and 23%, respectively. The fem ale wild-type mice had a mean mammary tumor multiplicity of 0.1 0.4, and the Brca2-de cient group had a mean mammary tumor multiplicity of 0.3 0.5. The tum or m ultiplicities obser ved in the females harboring an Apc m utation was statistically different than those observed in the wild-type and Brca2-de cient genotypic classes (p 0.001). M utations in the human BRCA2 gene have been associated with m ale breast cancer (9) . Male mice representing all 4 genotypic classes were included in the experiment to assess the effect of the Brca2 and Apc mutations on mamm ary tumor susceptibility. Male mice that inherited the Apc m utations, alone or in combination with a Brca2 alteration, developed mamm ary tumors with a very low incidence ( Table 2 ). Male Apc-mutant and Brca2/Apc double-mutant mice had mean tumor multiplicities of 0.4 0.5 and 0.2 0.3, respectively. The male wild-type and Brca2-de cient mice did not develop any mamm ary tumors. The difference in tumor multiplicities among m ale m ice of the different genotypic classes was not signi cant. However, the development of mammary tumors with a short latency in m ale mice with an inherited Apc Min mutation may be biologically relevant.
Histologic Evaluation of Mammary Tumors
The mammary tum ors examined from both m ale and fem ale mice were characterized as adenoacanthom as and are the same histologic type as observed in previous studies of m ammary tum or developm ent in Apc mutant m ice (27, 43) . This tumor type has been well described in the mouse mamm ary gland carcinogenesis literature to denote tumors with more than 25% keratinized, squamous epithelial cell differentiation (36) . Although the term ''adenoacanthom a'' m ight suggest a benign behavior, the tumors in this study were considered malignant. These neoplasms were generally characterized by the presence of undifferentiated acini and tubules that contained centrally con ned squamous cells and keratin ( Figure 1C , D). Most tumors contained various proportions of both adenomatous and squamous cell types, although a few ver y small lesions were predom inantly squam ous in appearance. These very small lesions might represent keratotic nodules or preneoplastic foci, but for the purpose of this report, all isolated lesions were considered adenoacanthom as. The tumors were locally invasive, expansile growths with little encapsulation. In ammation within and around the tum or was variable. In those tum ors with predominantly squamous differentiation, the in ammator y component was m oderate to marked with areas of brosis. Occasionally, the squam ous component became m arkedly cystic and lled with keratinous debris resembling keratoacanthomas of the skin. Neither invasion nor m etastases into the m amm ary lymph node were observed over the limited tim e course of this study.
Mammary Gland Ductal Morphogenesis
The pattern of mammary ductal m orphogenesis was studied in the #4 abdominal mamm ary glands isolated from the ENU -treated F1 offspring. The male Apc and Brca2/Apc double-mutant mouse m ammary ducts had undergone a modest degree of m orphogenesis com pared to their Brca2-de cient and wild-type litterm ates ( Figure 2) . The m ale m amm ary ducts from Apc-and Brca2/Apc-m utant mice were elongated and in most cases had extended to the lym ph node of the fourth mammary gland ( Figure  2C, D) . Male m ice are born with a small mammary gland rudiment similar to females, except without the presence of a nipple and not growing beyond the rudimentary stage. The observation of ductal morphogenesis in male mice that inherited an Apc m utation contrasted to the mamm ary glands from the wild-type and Brca2-de cient male mice in which the m ammary gland duct was either present as a rudim entar y structure or, in som e cases, not visible within the fat pad (Figure 2A, B ). No differences in mammary branching phenotype were noted among the different female groups in this study.
Apc Mutation Carriers Are Predisposed to Premature Ovarian Failure
The overall progression of follicular development in the ovaries isolated from the F1 offspring was assessed.
The reproductive tracts of the ENU -treated female m ice with Apc mutations displayed var ying degrees of ovarian histopathology. The Corpora lutea (CL) were absent in 26% of the Apc -mutant m ice and 22% of the Brca2/Apc double mutants (Table 3) , and the remaining follicles were typically degenerate. This incidence of arrested follicular development was 6-fold higher than that observed for the Brca2-de cient group and was statistically significant (p 0.05). In addition, com plete loss of follicles (ovarian atrophy) was observed in approxim ately onefourth of the Apc-mutant and double-heterozygous mice, while wild-type and Brca2-de cient m ice rarely displayed this phenotype (Figure 3 and Table 3 ). The progression from follicular degeneration to complete atrophy was interpreted to represent premature ovarian failure.
In addition, the uteri of the Apc-mutant and Brca2/Apc double-mutant ENU -treated females with ovarian failure were characterized as atrophic. The uterine endometrium and myom etrium appeared quiescent, rem iniscent of an immature appearance. It was not clear whether these reproductive organs of the Apc-mutant m ice had atrophied or had never developed fully. The vaginal epithelium was reduced in thickness and lined by vacuolated cells indicative of anestrus. 
Histological Analysis of Additional Tissues
The adrenal glands, pancreas, and a limited number of gastrointestinal tracts were also evaluated in this study. The gastrointestinal tracts were isolated from a small subset of animals representing each genotypic class. Animals with an Apc mutation developed m ultiple intestinal tumors, as expected, but no gross difference was apparent between Apc-de cient and double heterozygotes with regard to tumor multiplicity at this site (data not shown). Some mild pancreatic in amm ation was observed in all ENU -treated m ice, but overall the lesions present in the pancreas and adrenal glands were subtle and unremarkable. Female Brca2-de cient, Apc-, and Brca2/Apc double-m utant females displayed some adrenal hyperplasia, but none was obser ved in the males. In addition, mild testicular degeneration was obser ved in only 1 of 9 wildtype males, 1 of 10 Brca2-de cient males, 1 of 9 Apc-mutant males, and 1 of 8 Brca2/Apc double-heterozygous male m ice examined.
DISCUSSION
This study shows that the inheritance of an Apc Min mutation predisposes ENU -treated fem ale and male mice to mamm ary tum ors and, in the case of fem ale mice, to ovarian failure. The inheritance of the exon 10 Brca2 mutation did not alter m ammary tumor incidence, m ultiplicity, or size in female or male m ice harboring the Apc codon 850N alteration. Female mice with an inherited Apc M in mutation are highly sensitive to m ammary tumor induction by ENU. The 100% incidence observed in our study is higher than that reported previously by Moser et al (26) and may be attributable to C57BL/6 substrain variation or dietar y factors. ENU treatment of the C57BL/6 (Apc ) and C57BL/6 (B2 )(Apc ) mice may have ENU -INDUCED PATHOLOGY IN Apc Min MICE been suf cient to induce a maximal mammary tum or response that could be m odi ed only by suppression, such as that which is observed when the C57BL/6 Apc -mutant mice are crossed with the resistant AKR/J, CAST/Ei, BALB/cByJ, or C3H/He mouse strains (27, 44) . However, it is important to note that, to date, there have been no reports of increased mammary tumor incidence, either spontaneous or carcinogen induced, in female m ice heterozygous for a Brca2 mutation on several genetic backgrounds (15) . Thus, it is unclear whether partial or complete loss of Brca2 will promote carcinogenesis in the mouse mammary gland.
It is also possible that the Brca2 mutation did not m odify Apc-driven mamm ary carcinogenesis because these genes act in different pathways. For example, since tumors developed in the ENU -treated Apc mutant m ale mice and in fem ale mice with or without normal ovarian function, m ammary tum or development in Apc -mutant mice may progress through a pathway that does not require ovarian hormones. In contrast, because the risk of breast cancer in human BRCA2 mutation carriers m ay be increased by the use of oral contraceptives (42) and does not appear to be diminished by parity (18) , tum or developm ent likely depends on a hormone-responsive environment. Thus, Brca2 m ay not m odify Apc m utation-dependent mammary carcinogenesis because the Apc alteration can in uence tumorigenesis without ovarian hormones, while Brca2 acts in a hormonally dependent pathway.
The rst line of evidence supporting the conclusion that ENU -treated Apc tum ors are not dependent on ovarian horm ones is that m ammary tumors developed in both ENU-treated female C57BL/6 (Apc ) and C57B L/6 (B2 )(Apc ) mice, whether ovaries are m orphologically normal or are atrophied. Normal ovarian function has been demonstrated to contribute to m ammary carcinogenesis in rodents [reviewed in (17) ]. However, if m ammary tumorigenesis were driven by an endocrine m echanism in this Apc m odel system, then ovarian failure would be expected to be protective. Ovarian failure and degeneration was evident after analysis of the reproductive tracts collected from the female Apc-m utant and Brca2/Apc double-heterozygous mice. There appeared to be a progression from a cessation of ovulation and CL formation, to failure to ever ovulate and form CLs, to atrophy. This was characterized as premature ovarian failure since Apc -mutant and Brca2/ Apc double-heterozygous mice should be ovulating and forming CLs like their wild-type littermates. Although mammary ductal morphogenesis appeared norm al in mice with an Apc m utation, the uteri were markedly underdeveloped in mice with ovarian atrophy, providing functional evidence that the ovarian hormones, required for stim ulation of uterine developm ent, were lacking.
Because ovarian failure m ay have been due to changes in body weight, the association between these factors was evaluated. Although the mean body weight for the Apcmutant class was statistically reduced compared to the wild-type and Brca2-de cient group, the Brca2/Apc double-heterozygous class was not signi cantly different from the other treatment groups, suggesting that body weight did not play a major role in the observed ovarian phenotype. Instead, it is likely that the Apc-mutant m ice are genetically predisposed to premature ovarian failure. Other studies have shown that premature ovarian failure may predispose mice to tum or form ation (23) and that ovarian tum ors did develop in irradiated Apc1638N m ice on a CB6F1 background (6) . In addition, the observed ovarian failure and senile atrophy could have been exacerbated by the ENU treatment of Apc-mutant mice. Alkylating agents can cause follicular depletion followed by overproduction of pituitary gonadotropins, which can contribute to aberrant cellular proliferation and tumorigenesis (28) . The presence of an Apc mutation may be permissive to cell replication in the presence of ENUinduced DNA damage in the ovaries of Apc-mutant mice. Further studies will be required to establish the m echanistic basis for the observed ovarian pathology.
Another line of evidence that ovarian hormones may not be required for m amm ary tumorigenesis in the Apc mouse m odel comes from the observation that m ale m ice developed tumors. W hile mammary tumor incidence and multiplicity were low in the male m ice, tumor development was considered biologically relevant given its rare occurrence in wild-type male mice. In addition, the partial ductal morphogenesis observed in the m ale mice suggests that mutant Apc acts early in mamm ary gland growth and development. In females and m ales, norm al mammary gland growth is initiated from primordial buds and progresses to the rudim entar y structure present at birth. In males, no further development occurs because of the repressive effects of androgens, while in females, mammary ductal m orphogenesis and com plex branching are induced by the hormonal changes that occur at puberty (17) . However, the mammary ducts from ENUtreated male C57BL/6 (Apc ) and C57BL/6 (B2 )(Apc ) m ice are elongated and have a m ore complex branching structure compared to wild-type and Brca2-de cient mice. Thus, the mammary glands of the m ale ENU -treated Apc mutants had partially progressed along a developmental pathway usually reser ved for fem ales during puberty and may result from lost repression rather than from horm onal stimulation. Moreover, this partial m ammary growth that occurred in males with histologically normal testes likely contributed to tumor sensitivity in the ENU -treated Apc-mutant males.
W hile this study suggests that a Brca2 alteration does not m odify an Apc mutation in ENU -treated mice, genegene interactions can have striking effects on mamm ary tum or development in Apc-mutant m ice. For example, mammary tumor susceptibility in Apc-m utant mice is clearly enhanced by the coinheritance of a Tcf 1 gene m utation, which dem onstrates that the Apc mutation can accelerate mammary tumorigenesis in the absence of carcinogen treatm ent. Tcf 1 is expressed in the basal mammary and proliferating intestinal epithelium and is regulated by Tcf 4, a com ponent of the Apc pathway (34) . Tcf 1 / m ice are predisposed to spontaneous mamm ary gland adenomas and intestinal neoplasm s (34) . Apc Minmutant m ice that lack the Tcf 1 gene develop a 100% incidence of spontaneous mammary tumors by 2 months of age, a dram atic reduction in latency compared to m ice with either genetic defect alone. These mice also had a decreased latency and increased multiplicity of intestinal tumor development (34) . Thus, Tcf 1 and Apc appear to act synergistically to prevent tumor developm ent and, when disrupted, result in very rapid neoplastic growth.
The APC protein has been implicated as a negative regulator of the Wnt-signaling pathway, which is involved in processes ranging from embryonic development to tumor form ation (6) . APC mutations cause an accumulation of -catenin, which complexes with Tcf 4 and induces c-m yc expression (16, 20, 25) . This overexpression of c-myc can lead to rapid proliferation and the dysregulation of cell growth (16) . c-m yc is overexpressed in some breast carcinomas and cell lines, and its ampli cation has been suggested to be an early event in the progression of human breast cancer (5, 11) . Since the overexpression of c-myc has been observed in the absence of gene ampli cation, other regulatory m echanisms appear to activate c-myc expression (5, 11) . For exam ple, hepatocyte growth factor (HGF), which promotes m ammary epithelial ductal branching, is regulated in the m ammary gland with the highest levels of expression occurring during ductal m orphogenesis (46) . HGF treatm ent of mouse mammary cells leads to a transient decrease of GSK3 kinase activity and -catenin accumulation and, like m utant Apc, can result in Tcf /Lef activation (30) . Thus, the inheritance of a mutant APC gene m ay lead to dysregulated growth and tumor development through oncogenic and/or growth factor pathways. This concept is consistent with our suggestion that Apc mutations act early during m ammary tumorigenesis and are not dependent on ovarian horm ones.
Genes in the Wnt-signaling pathway have also been implicated in the development of skin tumors in both humans and m ice (7, 12, 13, 31, 35) . This may be relevant to the m amm ary tum ors that arise in Apc-m utant mice for 2 reasons. First, the adenoacanthomas result from the squam ous metaplasia of the m amm ary ductal epithelium (36) . Second, the mamm ary gland is a modi ed sebaceous gland embryologically derived from the thickening of the ectoderm , the sam e germ layer that gives rise to the epidermis (36) . Mutations in the -catenin gene have been associated with the development of pilom atricoma-like skin tumors in humans and mice (7, 12) . M embers of the Wnt protein fam ily have been associated with epidermal-dermal interaction in the skin and are expressed in keratinocytes (13, 35) . Finally, sustained c-myc activation in the skin induces papillom atosis and hyperplastic actinic keratosis (31) .
Neither mammary ductal m orphogenesis nor m ammary or ovarian tum or developm ent were evaluated in Apc-m utant m ice beyond 100 days of age because of a heavy intestinal tum or burden on the C57BL/6N genetic background . Examination of mamm ary ductal morphogenesis for longer periods has been achieved in Apc Min mice using the mammary fat pad clearance and transplantation technique (27) . Apc -mutant mammary cells were transplanted into cleared fat pads of syngeneic hosts, resulting in spontaneous and chem ically induced focal alveolar hyperplasias and tumors. The use of m ammary gland-speci c conditional heterozygous and/or homozygous-m utant Apc m ice would permit the study of gene inactivation in a tissue-speci c manner, and this ap-proach could circumvent the complication of tumor development at multiple sites (38) .
In summary, we propose that Brca2 and Apc m ay inuence tum or developm ent through independent pathways, with Apc acting early and Brca2 functioning during differentiated hormone-dependent states. Because of the strong in uence of the Apc m utation early in the neoplastic process, coinheritance of a Brca2 alteration was not obser ved to enhance tumorigenesis under these experim ental conditions.
